Asia Pacific Metaxalone Market was worth USD XX million in 2018 and estimated to be growing at a CAGR of XX%, to reach USD XX million by 2023. Metaxalone is a muscle relaxant and a pain reliever, available as a tablet.
Metaxalone is useful in relieving drug that is caused by strain, spraining and other musculoskeletal conditions. The problem of arthritis is high in the elderly population, which stimulates the use of these kind of drugs. It has sedative effect as well as a skeletal muscle relaxant effect on the body and helps relieve pain. The compound is freely soluble in chloroform, but insoluble in ether or water.
Factors fuelling the growth the market are increasing number of people suffering from musculoskeletal conditions like arthritis and others, increasing number of injuries caused during injuries and increasing geriatric population. However, there are some side effects like headaches, vomiting and nausea and complications in administration in combination with some other drugs are the key challenges hampering the market.
The Asia Pacific market for Metaxalone is segmented based on Indication and End User. Based on Indication it is divided into Bone Pain, Muscle Pain, Joint Pain, Tunnel Syndrome and Others. Based on End Users it is divided into Hospitals, Clinics and Others. Based on geographical analysis, the market is divided into regions of China, India, Japan, South Korea and Australia. China holds the major share in the market due to presence of market leaders as well as the presence of a stellar healthcare system. India is the fastest growing region due to increasing disposable income, growing awareness and increasing adoption rate. Based on End Users, Hospitals hold the major share in the market due to their easy accessibility and larger selling capacity.
Some of the key players dominating this market include Biosynth, Chunghwa Chemical Synthesis and Biotech, Sigma Aldrich, CDI Technology, Angelini, Pfizer, Aurum Pharmatech, Finetech Industry Limited, Biochem and Oxchem Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Indication
5.1.1 Introduction
5.1.2 Bone Pain
5.1.3 Muscle Pain
5.1.4 Tunnel Syndrome
5.1.5 Joint Pain
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Indication
5.1.8 Market Attractiveness Analysis, By Indication
5.1.9 Market Share Analysis, By Indication
5.2 End User
5.2.1 Introduction
5.2.2 Hospitals
5.2.3 Clinics
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By End User
5.2.6 Market Attractiveness Analysis, By End User
5.2.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Indication
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Indication
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Indication
6.1.5.3 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Biosynth
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Chunghwa Chemical Synthesis and Biotech
8.3 Sigma Aldrich
8.4 CDI Technology
8.5 Angelini
8.6 Pfizer
8.7 Aurum Pharmatech
8.8 Finetech Industry Limited
8.9 Biochem
8.10 Oxchem Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
